Test Price
2,800 AED✅ Home Collection Available
SMARCAD1 Gene Adermatoglyphia Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited Next-Generation Sequencing (NGS) processing.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test interpretation with a consultant medical geneticist included.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
This definitive genetic test identifies pathogenic variants in the SMARCAD1 gene responsible for autosomal dominant adermatoglyphia. The assay delivers binary positive/negative classification with greater than 99.9% analytical sensitivity, supporting dermatological, immunological, and osteological clinical management.
Test Overview & Methodology
The SMARCAD1 adermatoglyphia genetic test employs next-generation sequencing (NGS) to interrogate all coding regions and splice sites of the SMARCAD1 gene. This high-resolution approach detects single nucleotide variants, small insertions, and deletions with a sensitivity exceeding 99.9%. Congenital absence of fingerprints carries implications beyond dermatology, including potential immunological and osteological associations, making definitive molecular diagnosis essential for comprehensive patient care.
The assay is performed on peripheral whole blood, extracted DNA, or FTA card samples. No fasting is required. A mandatory pre-test genetic counselling session is conducted to draw a pedigree chart of affected family members and discuss the implications of SMARCAD1 gene variants. Results are correlated with clinical findings to avoid unnecessary distress from variants of unknown significance (VUS).
| Feature | Our Test (UAE) | Closest Alternative |
|---|---|---|
| Precision | NGS with 99.9% analytical sensitivity | Sanger sequencing or targeted panel |
| Method | Next-Generation Sequencing (NGS) | PCR-based assays |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I recognize the profound implications of genetic testing for adermatoglyphia. A positive finding of a variant of unknown significance in SMARCAD1 does not automatically predict full phenotypic expression. Clinical correlation with a dermatologist and genetic counsellor is essential to mitigate unnecessary anxiety. Genetic results should never be used as a standalone basis for treatment decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notice
Medication Continuity Warning
Never discontinue prescribed medications without explicit instruction from your treating physician. Genetic test results alone do not constitute a therapeutic recommendation. Always consult your doctor before altering any treatment regimen.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Patients with active febrile illness or systemic infection.
- Severe coagulopathy or ongoing anticoagulant therapy (requires specialist clearance).
- Age under 18 years without parental or guardian consent per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
Emergency Red Flags — Seek Immediate Care
- Prolonged bleeding or oozing from the venipuncture site lasting more than 30 minutes.
- Signs of infection: increasing redness, swelling, or purulent discharge at the collection site.
- Severe emotional distress or suicidal ideation triggered by receiving genetic results.
Patient FAQ & Clinical Guidance
1. What does the SMARCAD1 adermatoglyphia genetic test detect?
This test identifies pathogenic or likely pathogenic variants in the SMARCAD1 gene that cause autosomal dominant adermatoglyphia, providing definitive molecular confirmation. The NGS assay interrogates coding regions and splice sites with greater than 99.9% analytical sensitivity, delivering a clear positive or negative classification. Clinical correlation with a dermatologist is recommended for comprehensive interpretation.
2. How is the sample collected and what is the turnaround time?
Sample collection is performed via VIP mobile phlebotomy using a temperature-controlled cold-chain logistics system. Our DHA-licensed phlebotomist visits your home, office, or hotel daily between 8 AM and 11 PM. Acceptable specimen types include peripheral whole blood, extracted DNA, or a single drop on an FTA card. Results are reported within 3 to 4 weeks from sample receipt.
3. Is this genetic test legally authorized in the UAE?
Yes. The test is fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Informed consent is mandatory, and all genomic data is encrypted. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
4. What preparation is required before the test?
A comprehensive clinical history must be submitted. A mandatory pre-test genetic counselling session is scheduled to construct a pedigree chart of affected family members and discuss the implications of SMARCAD1 variants. No fasting is required. If you are on anticoagulant therapy, you must obtain clearance from your treating physician prior to blood collection.
5. What does a positive result mean for my health?
A positive result confirms a pathogenic or likely pathogenic variant in SMARCAD1, establishing the genetic basis for adermatoglyphia. This diagnosis may inform dermatological surveillance, immunological evaluation, and osteological assessment. However, a variant of unknown significance (VUS) does not always correlate with full phenotypic expression. Clinical correlation with a consultant medical geneticist and a dermatologist is vital to avoid unnecessary distress and to guide appropriate management.
UAE Regulatory & Data Privacy Adherence
- Data Protection: This test fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring all genomic and personal data is encrypted, access-controlled, and processed with explicit informed consent.
- Health Data Governance: Operations adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which mandates secure handling of electronic health records and telemedicine interactions.
- Clinical Safety & Consent: All specimen collection procedures and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring legal protection for both patients and practitioners.
- Accreditation: The laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | SMARCAD1 Gene Adermatoglyphia Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with 99.9% Analytical Sensitivity |
| ICD-10-CM Code | Q84.8 |
| LOINC Code | 81335-5 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians